Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilars and to the discovery and development of novel therapeutics for autoimmune indications. In July 2010, Momentaâs lead product (developed in collaboration with Sandoz) was approved as the first generic version of LOVENOXÂŽ (Enoxaparin Sodium Injection). In April 2015, the company announced the FDA approval of once daily GlatopaÂŽ 20 mg/mL (glatiramer acetate injection), a fully substitutable generic version of COPAXONEÂŽ 20 mg/mL. Glatopa was also developed in collaboration with Sandoz. The company's development pipeline includes a biosimilar version of HUMIRAÂŽ (adalimumab), a biosimilar version of ORENCIAÂŽ (abatacept) and a portfolio of five other early stage biosimilar programs in collaboration with Mylan and three novel drug candidates for autoimmune indications. Source
No articles found.
CAVU Biotherapies offers a comprehensive solution to prepare for, monitor, and tre...
CAVU Biotherapies offers a comprehensive soluti...
Anixa is focused on harnessing the bodyâs immune system in the fight against can...
Anixa is focused on harnessing the bodyâs imm...
Synthorx is a biotechnology company focused on prolonging and improving the lives ...
Synthorx is a biotechnology company focused on ...
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indicatio...
Kamada Ltd. is focused on plasma-derived protei...
China Biologic Products Holdings, Inc. (NASDAQ: CBPO), is a leading fully integrat...
China Biologic Products Holdings, Inc. (NASDAQ:...
An emerging leader in the specialty pharmaceuticals industry, ANI Pharmaceuticals ...
An emerging leader in the specialty pharmaceuti...
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...
Provention Bio, Inc. is a clinical-stage biopha...
Join the National Investor Network and get the latest information with your interests in mind.